207 related articles for article (PubMed ID: 20219488)
1. Trilostane in dogs.
Ramsey IK
Vet Clin North Am Small Anim Pract; 2010 Mar; 40(2):269-83. PubMed ID: 20219488
[TBL] [Abstract][Full Text] [Related]
2. The effect of trilostane treatment on circulating thyroid hormone concentrations in dogs with pituitary-dependent hyperadrenocorticism.
Kenefick SJ; Neiger R
J Small Anim Pract; 2008 Mar; 49(3):139-43. PubMed ID: 18086154
[TBL] [Abstract][Full Text] [Related]
3. Cortisol, aldosterone, cortisol precursor, androgen and endogenous ACTH concentrations in dogs with pituitary-dependant hyperadrenocorticism treated with trilostane.
Sieber-Ruckstuhl NS; Boretti FS; Wenger M; Maser-Gluth C; Reusch CE
Domest Anim Endocrinol; 2006 Jul; 31(1):63-75. PubMed ID: 16233969
[TBL] [Abstract][Full Text] [Related]
4. Update on the use of trilostane in dogs.
Lemetayer J; Blois S
Can Vet J; 2018 Apr; 59(4):397-407. PubMed ID: 29606727
[TBL] [Abstract][Full Text] [Related]
5. Evaluation of twice-daily, low-dose trilostane treatment administered orally in dogs with naturally occurring hyperadrenocorticism.
Vaughan MA; Feldman EC; Hoar BR; Nelson RW
J Am Vet Med Assoc; 2008 May; 232(9):1321-8. PubMed ID: 18447776
[TBL] [Abstract][Full Text] [Related]
6. Evaluation of the use of baseline cortisol concentration as a monitoring tool for dogs receiving trilostane as a treatment for hyperadrenocorticism.
Cook AK; Bond KG
J Am Vet Med Assoc; 2010 Oct; 237(7):801-5. PubMed ID: 20919845
[TBL] [Abstract][Full Text] [Related]
7. Long-term efficacy of trilostane administered twice daily in dogs with pituitary-dependent hyperadrenocorticism.
Alenza DP; Arenas C; Lopez ML; Melian C
J Am Anim Hosp Assoc; 2006; 42(4):269-76. PubMed ID: 16822765
[TBL] [Abstract][Full Text] [Related]
8. Evaluation of 2 trilostane protocols for the treatment of canine pituitary-dependent hyperadrenocorticism: twice daily versus once daily.
Arenas C; Melián C; Pérez-Alenza MD
J Vet Intern Med; 2013; 27(6):1478-85. PubMed ID: 24118316
[TBL] [Abstract][Full Text] [Related]
9. Persistent isolated hypocortisolism following brief treatment with trilostane.
Ramsey IK; Richardson J; Lenard Z; Tebb AJ; Irwin PJ
Aust Vet J; 2008 Dec; 86(12):491-5. PubMed ID: 19076773
[TBL] [Abstract][Full Text] [Related]
10. Evaluation of twice-daily lower-dose trilostane treatment administered orally in dogs with naturally occurring hyperadrenocorticism.
Feldman EC
J Am Vet Med Assoc; 2011 Jun; 238(11):1441-51. PubMed ID: 21627507
[TBL] [Abstract][Full Text] [Related]
11. Medical management of pituitary-dependent hyperadrenocorticism: mitotane versus trilostane.
Reine NJ
Clin Tech Small Anim Pract; 2007 Feb; 22(1):18-25. PubMed ID: 17542193
[TBL] [Abstract][Full Text] [Related]
12. Results of clinical examinations, laboratory tests, and ultrasonography in dogs with pituitary-dependent hyperadrenocorticism treated with trilostane.
Ruckstuhl NS; Nett CS; Reusch CE
Am J Vet Res; 2002 Apr; 63(4):506-12. PubMed ID: 11939311
[TBL] [Abstract][Full Text] [Related]
13. The use of trilostane for the treatment of alopecia X in Alaskan malamutes.
Leone F; Cerundolo R; Vercelli A; Lloyd DH
J Am Anim Hosp Assoc; 2005; 41(5):336-42. PubMed ID: 16141187
[TBL] [Abstract][Full Text] [Related]
14. Haptoglobin concentrations in dogs undergoing trilostane treatment for hyperadrenocorticism.
McGrotty YL; Arteaga A; Knottenbelt CM; Ramsey IK; Eckersall PD
Vet Clin Pathol; 2005 Sep; 34(3):255-8. PubMed ID: 16134074
[TBL] [Abstract][Full Text] [Related]
15. Efficacy of low- and high-dose trilostane treatment in dogs (< 5 kg) with pituitary-dependent hyperadrenocorticism.
Cho KD; Kang JH; Chang D; Na KJ; Yang MP
J Vet Intern Med; 2013; 27(1):91-8. PubMed ID: 23167780
[TBL] [Abstract][Full Text] [Related]
16. Monitoring the response of canine hyperadrenocorticism to trilostane treatment by assessment of acute phase protein concentrations.
Arteaga A; Dhand NK; McCann T; Knottenbelt CM; Tebb AJ; Evans H; Eckersall PD; Ramsey IK
J Small Anim Pract; 2010 Apr; 51(4):204-9. PubMed ID: 20406368
[TBL] [Abstract][Full Text] [Related]
17. Changes in ultrasonographic appearance of adrenal glands in dogs with pituitary-dependent hyperadrenocorticism treated with trilostane.
Mantis P; Lamb CR; Witt AL; Neiger R
Vet Radiol Ultrasound; 2003; 44(6):682-5. PubMed ID: 14703251
[TBL] [Abstract][Full Text] [Related]
18. Adrenocorticotropic hormone levels in dogs with pituitary-dependent hyperadrenocorticism following trilostane therapy.
Witt AL; Neiger R
Vet Rec; 2004 Mar; 154(13):399-400. PubMed ID: 15083974
[No Abstract] [Full Text] [Related]
19. Determination of the concentrations of trilostane and ketotrilostane that inhibit ex vivo canine adrenal gland synthesis of cortisol, corticosterone, and aldosterone.
McGraw AL; Whitley EM; Lee HP; Boothe DM; Behrend EN
Am J Vet Res; 2011 May; 72(5):661-5. PubMed ID: 21529218
[TBL] [Abstract][Full Text] [Related]
20. Update on drugs used to treat endocrine diseases in small animals.
Behrend EN
Vet Clin North Am Small Anim Pract; 2006 Sep; 36(5):1087-105, vii. PubMed ID: 16984828
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]